TC Biopharm (Holdings) Plc (TCBPY)
- Previous Close
0.3139 - Open
0.3000 - Bid 0.3000 x --
- Ask 0.3998 x 312500
- Day's Range
0.3000 - 0.3998 - 52 Week Range
0.0800 - 199.8400 - Volume
4,588 - Avg. Volume
217,703 - Market Cap (intraday)
715,037 - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-127.3200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
tcbiopharm.comRecent News: TCBPY
View MorePerformance Overview: TCBPY
Trailing total returns as of 5/17/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCBPY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCBPY
View MoreValuation Measures
Market Cap
715.04k
Enterprise Value
1.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.18
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-127.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--